High Cut-off Dialysis Membranes: Current Uses and Future Potential

Advances in Chronic Kidney Disease

Volumn 18, Issue 3, 2011, Pages 180-187

  Gondouin, Bertrand ^a   Hutchison, Colin A ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Hemodialysis; High cut off; Inflammation; Myeloma kidney; Severe sepsis syndrome

Indexed keywords

CYTOKINE; UREMIC TOXIN;

CLINICAL RESEARCH; DIALYSIS MEMBRANE; HEMODIALYSIS; HEMODIALYSIS PATIENT; KIDNEY; KIDNEY FAILURE; KIDNEY TUMOR; LIGHT CHAIN; MOLECULAR WEIGHT; MYELOMA; MYELOMA KIDNEY; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; SEPSIS;

CYTOKINES; HUMANS; KIDNEY FAILURE, CHRONIC; MEMBRANES, ARTIFICIAL; MULTIPLE MYELOMA; MYELOMA PROTEINS; MYOGLOBIN; POROSITY; RENAL DIALYSIS; RHABDOMYOLYSIS; SEPSIS; TOXINS, BIOLOGICAL;

EID: 79955451482     PISSN: 15485595     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ackd.2011.02.006     Document Type: Review

References (73)

1. Vanholder R., Baurmeister U., Brunet P., Cohen G., Glorieux G., Jankowski J. A bench to bedside view of uremic toxins. J Am Soc Nephrol 2008, 19:863-870. for the European Uremic Toxin Work Group.
2. Haase M., Bellomo R., Morgera S., et al. High cut-off point membranes in septic acute renal failure: a systematic review. Int J Artif Organs 2007, 30:1031-1041.
3. Hutchison C.A., Harding S., Mead G., et al. Serum free-light chain removal by high cutoff hemodialysis: optimizing removal and supportive care. Artif Organs 2008, 32:910-917.
4. Bagshaw S.M., Laupland K.B., Doig C.J., et al. Prognosis for long-term survival and renal recovery in critically ill patients with severe acute renal failure: a population-based study. Crit Care 2005, 9:R700-R709.
5. Naka T., Haase M., Bellomo R. 'Super high-flux' or 'high cut-off' hemofiltration and hemodialysis. Contrib Nephrol 2010, 166:181-189.
6. Uchino S., Bellomo R., Goldsmith D., et al. Cytokine removal with a large pore cellulose triacetate filter: an ex vivo study. Int J Artif Organs 2002, 25:27-32.
7. Uchino S., Bellomo R., Goldsmith D., et al. Super high flux hemofiltration: a new technique for cytokine removal. Intensive Care Med 2002, 28:651-655.
8. Morgera S., Haase M., Rocktäschel J., et al. High permeability haemofiltration improves peripheral blood mononuclear cell proliferation in septic patients with acute renal failure. Nephrol Dial Transplant 2003, 18:2570-2576.
9. Lee W.C., Uchino S., Fealy N., et al. Super high flux hemodialysis at high dialysate flows: an ex vivo assessment. Int J Artif Organs 2004, 27:24-28.
10. Uchino S., Bellomo R., Morimatsu H., et al. Cytokine dialysis: an ex vivo study. ASAIO J 2002, 48:650-653.
11. Haase M., Bellomo R., Baldwin I., et al. Hemodialysis membrane with a high-molecular-weight cutoff and cytokine levels in sepsis complicated by acute renal failure: a phase 1 randomized trial. Am J Kidney Dis 2007, 50:296-304.
12. Morgera S., Rocktäschel J., Haase M., et al. Intermittent high permeability hemofiltration in septic patients with acute renal failure. Intensive Care Med 2003, 29:1989-1995.
13. Morgera S., Kraft A.K., Siebert G., Luft F.C., Neumayer H.H. Long-term outcomes in acute renal failure patients treated with continuous renal replacement therapies. Am J Kidney Dis 2002, 40:275-279.
14. Morgera S., Haase M., Kuss T., et al. Pilot study on the effects of high cutoff hemofiltration on the need for norepinephrine in septic patients with acute renal failure. Crit Care Med 2006, 34:2099-2104.
15. Sanders P.W., Booker B.B. Pathobiology of cast nephropathy from human Bence Jones proteins. J Clin Invest 1992, 89:630-639.
16. Hutchison C.A., Basnayake K., Cockwell P. Serum free light chain assessment in monoclonal gammopathy and kidney disease. Nat Rev Nephrol 2009, 5:621-628.
17. Leung M.A., Gertz S.R., Zeldenrust S.V., et al. Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains. Kidney Int 2008, 73:1282-1288.
18. Zucchelli P., Pasquali S., Cagnoli L., Ferrari G. Controlled plasma exchange trial in acute renal failure due to multiple myeloma. Kidney Int 1988, 33:1175-1180.
19. Hutchison C.A., Cockwell P., Reid S., et al. Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies. J Am Soc Nephrol 2007, 18:886-895.
20. Cserti C., Haspel R., Stowell C., Dzik W. Light-chain removal by plasmapheresis in myeloma-associated renal failure. Transfusion 2007, 47:511-514.
21. Clark W.F., Stewart A.K., Rock G.A., et al. When myeloma presents as acute renal failure: a randomized, controlled trial. Ann Intern Med 2005, 143:777-784.
22. Bachmann U., Schindler R., Storr M., Kahl A., Joerres A., Sturm I. Combination of bortezomib-based chemotherapy and extracorporeal free light chain removal for treating cast nephropathy in multiple myeloma. NDT Plus 2008, 1:106-108.
23. Hutchison C.A., Bradwell A.R., Cook M., et al. Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis. Clin J Am Soc Nephrol 2009, 4:745-754.
24. Hutchison C., Basnayake K., Cook M., et al. Free light chain removal hemodialysis increases renal recovery rate and improves patient survival in patients with cast nephropathy. Nephrol Dial Transplant 2008, 23:SO019a.
25. Ludwig H., Adam Z., Hajek R., et al. Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study. J Clin Oncol 2010, 28:4635-4641.
26. Dimopoulos M.A., Roussou M., Gavriatopoulou M., et al. Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors. Clin Lymphoma Myeloma 2009, 9:302-306.
27. Basnayake K., Cheung C.K., Sheaff M., et al. Differential progression of renal scarring and determinants of late renal recovery in sustained dialysis dependent acute kidney injury secondary to myeloma kidney. J Clin Pathol 2010, 63:884-887.
28. Hutchison C.A., Plant T., Drayson M., et al. Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure. BMC Nephrol 2008, 9:11.
29. Hutchison C.A., Cook M., Heyne N., et al. European trial of free light chain removal by extended haemodialysis in cast nephropathy (EuLITE): a randomised control trial. Trials 2008, 9:55-61.
30. Mikkelsen T.S., Toft P. Prognostic value, kinetics and effect of CVVHDF on serum of the myoglobin and creatine kinase in critically ill patients with rhabdomyolysis. Acta Anaesthesiol Scand 2005, 49:859-864.
31. Brown C.V., Rhee P., Chan L., et al. Preventing renal failure in patients with rhabdomyolysis: do bicarbonate and mannitol make a difference?. J Trauma 2004, 56:1191-1196.
32. de Meijer A.R., Fikkers B.G., de Keijzer M.H., van Engelen B.G.M., Drenth J.P.H. Serum creatine kinase as predictor of clinical course in rhabdomyolysis: a 5-year intensive care survey. Intensive Care Med 2003, 29:1121-1125.
33. Singhal P.C., Rubin R.B., Peters A., Santiago A., Neugarten J. Rhabdomyolysis and acute renal failure associated with cocaine abuse. J Toxicol Clin Toxicol 1990, 28:321-330.
34. Ward M.M. Factors predictive of acute renal failure in rhabdomyolysis. Arch Intern Med 1988, 148:1553-1557.
35. Bosch X., Poch E., Grau J.M., et al. Rhabdomyolysis and acute kidney injury. N Engl J Med 2009, 361:62-72.
36. Naka T., Jones D., Baldwin I., et al. Myoglobin clearance by super high-flux hemofiltration in a case of severe rhabdomyolysis: a case report. Crit Care 2005, 9:R90-R95.
37. Basnayake K., Cockwell P., Hutchison C.A. Rhabdomyolysis and acute kidney injury. N Engl J Med 2009, 361:1411-1413.
38. Heyne N., Guthoff M., Weisel K.C. Rhabdomyolysis and acute kidney injury. N Engl J Med 2009, 361:1412.
39. Collins A.J., Foley R., Herzog C., et al. Excerpts from the United States renal data system 2007 annual data report. Am J Kidney Dis 2008, 51:S1-S320.
40. Cohen G., Hörl W.H. Progress in uremic toxin research: resistin as a cardiovascular and atherosclerotic risk factor and uremic toxin. Semin Dial 2009, 22:373-377.
41. Cohen G., Haag-Weber M., Horl W.H. Immune dysfunction in uremia. Kidney Int Suppl 1997, 62:S79-S82.
42. Cohen G., Ilic D., Raupachova J., Hörl W.H. Resistin inhibits essential functions of polymorphonuclear leukocytes. J Immunol 2008, 181:3761-3768.
43. Cohen G., Haag-Weber M., Mai B., Deicher R., Horl W.H. Effect of immunoglobulin light chains from hemodialysis and continuous ambulatory peritoneal dialysis patients on polymorphonuclear leukocyte functions. J Am Soc Nephrol 1995, 6:1592-1599.
44. Cohen G., Rudnicki M., Horl W.H. Uremic toxins modulate the spontaneous apoptotic cell death and essential functions of neutrophils. Kidney Int Suppl 2001, 78:S48-S52.
45. Vanholder R., Van Laecke S., Verbeke F., et al. Uraemic toxins and cardiovascular disease: in vitro research versus clinical outcome studies. NDT Plus 2008, 1:2-10.
46. Stenvinkel P., Ketteler M., Johnson R.J., et al. IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia-the good, the bad, and the ugly. Kidney Int 2005, 67:1216-1233.
47. Kimmel P.L., Phillips T.M., Simmens S.J., et al. Immunologic function and survival in hemodialysis patients. Kidney Int 1998, 54:236-244.
48. Stenvinkel P., Carrero J.J., Axelsson J., Lindholm B., Heimbürger O., Massy Z. Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle?. Clin J Am Soc Nephrol 2008, 3:505-521.
49. Jankowski V., Tölle M., Vanholder R., et al. Uridine adenosine tetraphosphate: a novel endothelium- derived vasoconstrictive factor. Nat Med 2005, 11:223-227.
50. Axelsson J., Bergsten A., Qureshi A.R., et al. Elevated resistin levels in chronic kidney disease are associated with decreased glomerular filtration rate and inflammation, but not with insulin resistance. Kidney Int 2006, 69:596-604.
51. Fishbane S., Galgano C., Langley R.C., Canfield W., Maesaka J.K. Reticulocyte hemoglobin content in the evaluation of iron status of hemodialysis patients. Kidney Int 1997, 52:217-222.
52. Witko-Sarsat V., Friedlander M., Nguyen K.T., et al. Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 1998, 161:2524-2532.
53. Glorieux G.L., Dhondt A.W., Jacobs P., et al. In vitro study of the potential role of guanidines in leukocyte functions related to atherogenesis and infection. Kidney Int 2004, 65:2184-2192.
54. Makita Z., Radoff S., Rayfield E.J., et al. Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 1991, 325:836-842.
55. Liu S.X., Hou F.F., Guo Z.J., et al. Advanced oxidation protein products accelerate atherosclerosis through promoting oxidative stress and inflammation. Arterioscler Thromb Vasc Biol 2006, 26:1156-1162.
56. Jourde-Chiche N., Dou L., Cerini C., Dignat-George F., Vanholder R., Brunet P. Progress in uremic toxin research: protein-bound toxins-update 2009. Semin Dial 2009, 22:334-339.
57. Barreto F.C., Barreto D.V., Liabeuf S., et al. Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clin J Am Soc Nephrol 2009, 4:1551-1558.
58. Meijers B.K.I., Claes K., Bammens B., et al. p-cresol and cardiovascular risk in mild-to-moderate kidney disease. Clin J Am Soc Nephrol 2010, 5:1182-1189.
59. Lin C.J., Wu C.J., Pan C.F., Chen Y.C., Sun F.J., Chen H.H. Serum protein-bound uraemic toxins and clinical outcomes in hemodialysis patients. Nephrol Dial Transplant 2010, 25:3693-3700.
60. Massy Z.A., Ceballos I., Chadefaux-Vekemens B., et al. Homocyst(e)ine, oxidative stress, and endothelium function in uremic patients. Kidney Int Suppl 2001, 78:S243-S245.
61. Dou L., Jourde-Chiche N., Faure V., et al. The uremic solute indoxyl sulfate induces oxidative stress in endothelial cells. J Thromb Haemost 2007, 5:1302-1308.
62. Faure V., Dou L., Sabatier F., et al. Elevation of circulating endothelial microparticles in patients with chronic renal failure. J Thromb Haemost 2006, 4:566-573.
63. Pifer T.B., McCullough K.P., Port F.K., et al. Mortality risks in hemodialysis patients and changes in nutritional indicators: DOPPS. Kidney Int 2002, 62:2238-2245.
64. Dwyer J., Larive B., Leung J., et al. Are nutritional status indicators associated with mortality in the hemodialysis (HEMO) study?. Kidney Int 2005, 68:1766-1776.
65. Bammens B., Evenepoel P., Keuleers H., Verbeke K., Vanrenterghem Y. Free serum concentrations of the protein-bound retention solute p-cresol predict mortality in hemodialysis patients. Kidney Int 2006, 69:1081-1087.
66. Roy D., Quiles J., Gaze D.C., Collinson P., Kaski J.C., Baxter G.F. Role of reactive oxygen species on the formation of the novel diagnostic marker ischaemia modified albumin. Heart 2006, 92:113-114.
67. Sharma R., Gaze D.C., Pellerin D., et al. Ischemia-modified albumin predicts mortality in ESRD 2006. Am J Kidney Dis 2006, 47:493-502.
68. Locatelli F., Martin-Malo A., Hannedouche T., et al. Effect of membrane permeability on survival of hemodialysis patients. J Am Soc Nephrol 2009, 20:645-654.
69. Cheung A., Levin N., Greene T., et al. Effects of high-flux hemodialysis on clinical outcomes: results of the HEMO study. J Am Soc Nephrol 2003, 14:3251-3263.
70. Cheung A., Sarnak M., Yan G., et al. Cardiac diseases in maintenance hemodialysis patients: results of the HEMO study. Kidney Int 2004, 65:2381-2389.
71. Cheung A., Greene T. Effect of membrane permeability on survival of hemodialysis patients. J Am Soc Nephrol 2009, 20:462-464.
72. Hutchison C.A., Meryon I., Drayson Mark High cut-off hemodialysis lowers inflammatory status in chronic dialysis patients. J Am Soc Nephrol 2008, 19:TH-PO707a.
73. Zickler D., Epple C., Lun A., et al. Randomized controlled trial with high-cutoff-membranes in chronic hemodialysis patients: humoral and cellular markers of inflammation. J Am Soc Nephrol 2009, 20:SA-FC386.